FDA批准雅培HCV基因型检测试剂盒上市

2013-07-13 MedSci MedSci原创

  2013年6月20日,美国食品与药物管理局(FDA)批准了可检测到患者携带的丙型肝炎病毒(HCV)基因型的试剂盒(Abbott RealTime HCV Genotype II)上市,该试剂盒可对感染者的血清或血浆标本鉴别出基因型1、1a、1b、2、3、4和5。 该检测方法获准用于已知的HCV慢性感染者的鉴别诊断,而不用于血液遗传物质、血制品或组织供者的

HCV

  2013年6月20日,美国食品与药物管理局(FDA)批准了可检测到患者携带的丙型肝炎病毒(HCV)基因型的试剂盒(Abbott RealTime HCV Genotype II)上市,该试剂盒可对感染者的血清或血浆标本鉴别出基因型1、1a、1b、2、3、4和5。

 该检测方法获准用于已知的HCV慢性感染者的鉴别诊断,而不用于血液遗传物质、血制品或组织供者的筛查或诊断。该检测尚未在新生儿、儿科患者或免疫不全的患者(如AIDS)中进行评估。

  因不同的HCV基因型对应着不同的药物治疗方法,因此了解了患者感染的HCV基因型可给予其适宜的治疗方法,从而改善其转归。根据美国疾病控制与预防中心(CDC)的数据,HCV是美国最常见的慢性血液传播疾病,并且是肝移植的主要原因。

  英文链接:FDA approves first genotyping test for patients with hepatitis C
virus

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
    2013-08-24 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
    2013-09-03 bugit
  6. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
    2013-07-15 ymljack
  7. [GetPortalCommentsPageByObjectIdResponse(id=1890794, encodeId=a9851890e94ec, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Apr 23 15:51:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934629, encodeId=2be9193462989, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Wed Apr 16 18:51:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991058, encodeId=ffdc19910588b, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Aug 24 08:51:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992612, encodeId=b42119926125c, content=<a href='/topic/show?id=b9f562561a1' target=_blank style='color:#2F92EE;'>#检测试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62561, encryptionId=b9f562561a1, topicName=检测试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Jan 21 14:51:00 CST 2014, time=2014-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839239, encodeId=e257183923959, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Sep 03 21:51:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257567, encodeId=ca33125e5675d, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579909, encodeId=562e15e990985, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Mon Jul 15 04:51:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]

相关资讯

JH:慢性丙型肝炎患者病毒学治愈后肝纤维化可缓慢消退

慢性丙型肝炎既是一种病毒性感染疾病,也是一种肝纤维化疾病。对于实现持续病毒学应答(SVR)且伴有肝纤维化患者,仍存在发生并发症的可能。由于无法反复对患者进行肝活检,因此,还没有相应的研究对慢性丙型肝炎治疗前后肝纤维化的动力学特征进行评估。Fibrotest已被确证是表征肝纤维化进展和消退的生物标志物,具有与肝活检相当的预测价值。 基于上述情况,来自法国巴黎肝脏中心的Thierry Poynard

J HEPATOL:多学科支持计划提高慢性丙肝患者依从性及抗病毒治疗有效性

对于慢性丙型肝炎(CHC)患者来说,坚持抗病毒治疗对于获得持续病毒学应答(SVR)是非常重要的。因此,来自西班牙Hospital del Mar医院肠胃病学部门的José A. Carrión博士及其同事展开一项研究,旨在评估了一项多学科支持计划(MSP)对于提高CHC病患依从性和增加聚乙二醇干扰素α-2a和利巴韦林治疗有效性的作用,该计划以已发表的HIV治疗经验为依据。该研究结果在线发表于201

JH:根据慢性丙肝患者肌苷三磷酸酶基因多态性可预测严重贫血的发生

贫血是丙型肝炎三联疗法——特拉匹韦(TVR)联合聚乙二醇干扰素(PEG-IFN)α和利巴韦林(RBV)的常见副作用之一。相比于单独使用PEG-IFNα和RBV,联用TVR的贫血发生率更高。因此,来自日本九州大学医院的Jun Hayashi教授(MD,PhD)等人展开一项研究,研究结果在线发表于2013年5月28日的Journal of Hepatology(《肝脏病学杂志》)上。作者发现,慢性丙型

EASL 2013:慢性丙型病毒性肝炎研究进展

  第48届欧洲肝脏研究协会年会(EASL 2013 )于2013年4月24日至28日在荷兰—阿姆斯特丹 RAI会议中心隆重召开。南方医科大学南方医院肝病中心的侯金林 等人分享了来自EASL上关于慢性丙型病毒性肝炎研究的相关进展。慢性丙型病毒性肝炎(CHC)研究相关进展  近年来,多种直接抗病毒药物(DAA)的研发,开启了无干扰素抗丙型肝炎病毒(HCV)治疗的新时代。此次EAS

DDW 2013:NAFLD患者死亡危险因素仍然不明

      在2013消化疾病周(DDW)上公布的一项研究显示,非酒精性脂肪性肝病(NAFLD)患者的死亡因素包括老年、男性、躯干性肥胖和高密度脂蛋白胆固醇(HDL-C)水平低,换言之,与心血管疾病死亡和其他原因死亡的危险因素相同。另一方面,NAFLD患者的丙氨酸转氨酶(ALT)水平升高与死亡或其他不良结局风险增加无关,这意味着研究者需更

中国丙型肝炎流行病学状况与反思

       丙型肝炎是由HCV 感染而导致的一种传播途径明确、起病隐匿、慢性化程度高的疾病。HCV 感染呈全球性流行状态,是导致肝硬化和肝癌的最主要病因。最近世界卫生组织公布的数据表明,HCV 全球流行率为3% ,大约有1.7 亿人感染HCV 。而每年新发病例约3.5 万。   HCV 的感染率在不同国家、地区之间存在较大差异。世界范围内以埃及的流行